Synonym
NBI 27914 Free Base; NBI27914; NBI-27914
IUPAC/Chemical Name
4,6-Pyrimidinediamine, 5-chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-n-(2,4,6-trichlorophenyl)
InChi Key
GWLHYBQAZOGDLX-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H20Cl4N4/c1-3-6-26(16-13(20)7-12(19)8-14(16)21)18-15(22)17(24-10(2)25-18)23-9-11-4-5-11/h7-8,11H,3-6,9H2,1-2H3,(H,23,24,25)
SMILES Code
ClC1=C(N(CCC)C2=NC(C)=NC(NCC3CC3)=C2Cl)C(Cl)=CC(Cl)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
NBI-27914 is a potent and selective antagonist of CRFR1.
In vivo activity:
Specifically, bilateral intra-dlBNST injections of the CRF type 1 receptor antagonist NBI27914 increased intra-nucleus accumbens dopamine release and induced reward-related behaviors in rats with chronic pain.
Reference: Neurosci Lett. 2020 May 29;728:134958. https://pubmed.ncbi.nlm.nih.gov/32278943/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
434.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Hara R, Asaoka Y, Takahashi D, Nomura H, Amano T, Minami M. Disappearance of the inhibitory effect of neuropeptide Y within the dorsolateral bed nucleus of the stria terminalis in rats with chronic pain. Neurosci Lett. 2020 May 29;728:134958. doi: 10.1016/j.neulet.2020.134958. Epub 2020 Apr 9. PMID: 32278943.
2. Ji G, Neugebauer V. Contribution of Corticotropin-Releasing Factor Receptor 1 (CRF1) to Serotonin Receptor 5-HT2CR Function in Amygdala Neurons in a Neuropathic Pain Model. Int J Mol Sci. 2019 Sep 6;20(18):4380. doi: 10.3390/ijms20184380. PMID: 31489921; PMCID: PMC6770811.
In vivo protocol:
1. Hara R, Asaoka Y, Takahashi D, Nomura H, Amano T, Minami M. Disappearance of the inhibitory effect of neuropeptide Y within the dorsolateral bed nucleus of the stria terminalis in rats with chronic pain. Neurosci Lett. 2020 May 29;728:134958. doi: 10.1016/j.neulet.2020.134958. Epub 2020 Apr 9. PMID: 32278943.
2. Ji G, Neugebauer V. Contribution of Corticotropin-Releasing Factor Receptor 1 (CRF1) to Serotonin Receptor 5-HT2CR Function in Amygdala Neurons in a Neuropathic Pain Model. Int J Mol Sci. 2019 Sep 6;20(18):4380. doi: 10.3390/ijms20184380. PMID: 31489921; PMCID: PMC6770811.
1: Bhattacharya S, Subramanian G, Hall S, Lin J, Laoui A, Vaidehi N. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1. J Comput Aided Mol Des. 2010 Aug;24(8):659-74. doi: 10.1007/s10822-010-9364-2. Epub 2010 May 29. PMID: 20512399.
2: Prater CM, Harris BN, Carr JA. Tectal CRFR1 receptor involvement in avoidance and approach behaviors in the South African clawed frog, Xenopus laevis. Horm Behav. 2020 Apr;120:104707. doi: 10.1016/j.yhbeh.2020.104707. Epub 2020 Feb 6. PMID: 32001211.
3: Martínez V, Taché Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res. 2001 Mar 2;893(1-2):29-35. doi: 10.1016/s0006-8993(00)03277-7. PMID: 11222989.
4: Kubo Y, Kumano A, Kamei K, Amagase K, Abe N, Takeuchi K. Urocortin prevents indomethacin-induced small intestinal lesions in rats through activation of CRF2 receptors. Dig Dis Sci. 2010 Jun;55(6):1570-80. doi: 10.1007/s10620-009-0930-1. Epub 2009 Aug 26. PMID: 19707872.
5: Yarushkina NI, Filaretova LP. The peripheral corticotropin-releasing factor (CRF)-induced analgesic effect on somatic pain sensitivity in conscious rats: involving CRF, opioid and glucocorticoid receptors. Inflammopharmacology. 2018 Apr;26(2):305-318. doi: 10.1007/s10787-018-0445-5. Epub 2018 Feb 5. PMID: 29404882.
6: Zhu J, Chen Z, Tian J, Meng Z, Ju M, Wu G, Tian Z. miR-34b attenuates trauma- induced anxiety-like behavior by targeting CRHR1. Int J Mol Med. 2017 Jul;40(1):90-100. doi: 10.3892/ijmm.2017.2981. Epub 2017 May 9. PMID: 28498394; PMCID: PMC5466391.
7: Prater CM, Harris BN, Carr JA. Tectal CRFR1 receptors modulate food intake and feeding behavior in the South African clawed frog Xenopus laevis. Horm Behav. 2018 Sep;105:86-94. doi: 10.1016/j.yhbeh.2018.07.013. Epub 2018 Aug 8. PMID: 30077740.
8: Hummel M, Cummons T, Lu P, Mark L, Harrison JE, Kennedy JD, Whiteside GT. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology. 2010 Sep;59(3):160-6. doi: 10.1016/j.neuropharm.2010.05.001. Epub 2010 May 12. PMID: 20470804.
9: Jia FY, Li XL, Li TN, Wu J, Xie BY, Lin L. Role of nesfatin-1 in a rat model of visceral hypersensitivity. World J Gastroenterol. 2013 Jun 14;19(22):3487-93. doi: 10.3748/wjg.v19.i22.3487. PMID: 23801843; PMCID: PMC3683689.
10: Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol. 2003 Mar;63(3):751-65. doi: 10.1124/mol.63.3.751. Erratum in: Mol Pharmacol. 2005 Jul;68(1):260. PMID: 12606786.
